Author + information
- Ying Xian,
- Tracy Wang,
- Lisa Kaltenbach,
- Mark Effron,
- Timothy Henry,
- Richard Bach,
- Marjorie Zettler,
- Paul Vaitkus,
- Gregg Fonarow and
- Eric Peterson
CURRENT-OASIS 7 found no difference in 30-day outcomes between low and higher dose aspirin (ASA) groups post-AMI. The association of ASA dosing with long-term outcomes among contemporary AMI patients treated with PCI and dual antiplatelet therapy remains uncertain.
Use of low vs. higher dose (<162 mg vs. >162 mg daily) ASA at discharge was studied among 6,045 AMI patients treated with PCI at 209 U.S. hospitals in the TRANSLATE-ACS observational study from 4/2010–8/2012. We compared 6-month risks of MACE (composite of death, MI, stroke, or unplanned revascularization) and rehospitalization with bleeding between groups using multivariable Cox models.
Overall, 1808 patients (30%) received low dose ASA at discharge. Patients prescribed low dose ASA were older, more often had prior MI, stroke/TIA, or diabetes. Compared with higher dose patients, those prescribed low dose ASA had similar rates of STEMI (50.0% vs. 52.7%), but were more likely to receive bare metal stents (34.5% vs. 26.9%, p<0.001) or 2nd generation ADP inhibitors (prasugrel or ticagrelor) at discharge (31.8% vs. 27.7%, p=0.001). There were no significant differences in adjusted 6-month MACE and bleeding risks between patients discharged on low vs. higher dose ASA (Table).
Low dose ASA is prescribed at discharge in less than one-third of PCI-treated AMI patients in the U.S. There was no significant difference in 6-month risks of cardiovascular events and bleeding between dosing groups.
West, Room 3004
Sunday, March 10, 2013, 9:15 a.m.-9:30 a.m.
Session Title: ACS: Outcomes
Abstract Category: 1. Acute Coronary Syndromes: Clinical
Presentation Number: 913-8
- 2013 American College of Cardiology Foundation